Watch Session 1

What does diversity involve clinically? – Marie von Lilienfeld-Toal (Univ. Bochum, DE) – did not consent to publish her presentation/recording

CDDF Diversity in Clinical Trials Initiative – Fergus Sweeney (CDDF, IE)

Stakeholder Perspectives Towards Enrolling Representative Oncology Clinical Trials – Kim Lyerly (AAADV, US)

Watch the full session 2 

Progress and challenges in the use of endpoints in cancer drug development: the multiple myeloma experience – Bruno Paiva (Clínica Universidad de Navarra, ES)

EMA Perspective on the endpoints in cancer drug development – Francesco Pignatti (EMA, NL) – did not consent

Introduction on MPAACT – Harindra Abeysinghe

Watch session 3

ACT EU – Clinical Trial Methodology – Anja Schiel (NoMA, NO) on behalf of Kit Roes (EMA, NL)

Use of External Control Arm to Support Regulatory Approval: Case study of Pembrolizumab and Lenvatinib Combination – Alexandra Oger (MSD, FR)

Use of External Data for Efficient and Robust Evidence Generation: A Case Study of Dynamic Borrowing with External Control for Overall Survival – Emma Clark (Roche, UK)

Beyond randomization: an EORTC academic perspective – Murielle Mauer (EORTC, BE)

Introduction to panel discussion – Anja Schiel (NoMA, NO)

Watch session 4

Precision oncology – early development in view of the new regulations – Kate Simon (Bayer, US)

New regulations impact on academic research and patient care – Alberto Hernando (Vall d’Hebron Institute of Oncology, ES)

COMBINE – updates and outcomes – Ditte Zerlang Anderson (DKMA, DK)

Watch Session 5

Inequalities in approval process in EU – Carin Uyl-de Groot (Erasmus University Rotterdam, NL)

Lessons Learned from EMA/HTA Scientific Advice: An Industry Regulatory Perspective – Assia Dembri (BMS, CH)

The Impact of Patient Presence in HTA: Overcoming Barriers with a Realistic Perspective – Natacha Bolaños (Lymphoma Coalition, ES)

From Approval to HTA, 2025 and beyond – Anja Schiel (NoMA, NO)